Decentralized Trials STREAM

31. Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy 5/23/2022

    In this free webinar, learn how to update your clinical data strategy that ensures you can scale trials globally while decreasing the overall burden on sites and patients.

32. Leveraging Mobile Research Nurses For Clinical Trial Success In Vulnerable Patient Populations 8/26/2022

    Dr. Steven Cummings highlights the role of PCM Trials certified mobile research nurses in making possible large-scale home-based clinical trial.

33. The New Era Of Evidence Generation In Clinical Trials 6/19/2024

    Learn how top pharmaceutical companies are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.

34. Patient-Centric Cardiac Monitoring For Decentralized And Hybrid Trials 5/21/2025

    A patient-centric approach to cardiac monitoring is helping to advance data collection and reliability during decentralized and hybrid clinical trials.

35. What It Really Takes To Adopt eConsent Across Large Pharma 3/27/2024

    Explore the benefits of incorporating consent management technology and discover practical strategies for developing effective change management and training programs.

36. A Framework For Selecting Reliable Clinical Endpoints From Real-World DHT Data 2/25/2025

    Dr. Andy Liu presents a case study determining which digital measure of physical activity would be a well-defined and reliable clinical endpoint in a trial including patients with diabetes.

37. Site Support: The Cornerstone Of The Digital Trial Evolution 5/21/2024

    Follow along as this panel of experts shares key insights from their experiences, highlighting the technologies and processes that lead to successful partnerships in patient-centric digital trials.

38. Digital Physical Activity Measures In Phase 3 Immunology Trials 2/25/2025

    Dr. Jie Shen, Research Fellow and Director of Digital Science at AbbVie, shares lessons learned from incorporating digital measures of physical activity into Phase 3 immunology clinical trials.